DERM · CIK 1867066
What Journey Medical Corp. told the SEC could break it.
Journey Medical's disclosures reflect a small dermatology drugmaker that owns no manufacturing and operates under financial and pricing constraints. It relies entirely on third-party contract manufacturers — some outside the U.S. — to produce its products, exposing it to cGMP-compliance and supply-disruption risk, and because it imports products from India it could be hit by higher tariffs or sanctions on goods from India and China that raise its cost of goods. Its SWK credit facility is secured by substantially all its assets, restricts dividends and carries revenue and liquidity covenants, and it flags drug-pricing reform — a May 2025 most-favored-nation pricing executive order and IRA measures — that could pressure reimbursement and its pricing.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs on imports from India and Chinamedium
Journey imports products from India and faces possible higher tariffs/sanctions on goods from India and China, which could raise its cost of goods to commercialize products.
“Additional and higher tariffs and sanctions may be imposed on goods imported from India (from which we import products), China and other countries which could increase the cost of goods needed to commercialize our products and development of any future product candidates.”
SEC filing →As of 2026 - drug-pricing reform (most-favored-nation EO, IRA, Medicare/Medicaid)medium
A May 2025 most-favored-nation pricing executive order directs HHS to align US prescription-drug prices with comparable nations; reductions in Medicare/Medicaid reimbursement could flow through to private payors and pressure Journey's pricing.
“In May 2025, President Trump issued an executive order implementing the concept of most-favored nation pricing.”
Liquidity & debt
- SWK secured credit facility with revenue/liquidity covenantsmedium
Journey's SWK credit facility is secured by substantially all assets, restricts dividends and carries revenue and liquidity covenants, with quarterly principal repayments (~$1.9M) underway.
“The Credit Agreement also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all of our assets.”
SEC filing →As of 2026
Supplier concentration
- no internal manufacturing; reliance on third-party CMOs (some outside US)medium
Journey Medical has no internal manufacturing and relies entirely on third-party contract manufacturers — some located outside the US — to produce its products, exposing it to CMO cGMP compliance and supply disruption.
“We currently rely upon multiple contract manufacturers to produce our products and clinical supply of product candidates, some of which are located outside of the U.S., and will continue to rely upon contract manufacturers for any current or future product candidates under current Good Manufacturing Practice (“cGMP”) regulations for use in pre-clinical and clinical activities.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Cutia Therapeutics (HK) Limited
“The Company has agreed to supply the finished licensed products to Cutia for clinical and commercial use at an agreed price.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch